AIM

Cerillion to Demonstrate Groundbreaking GenAI-powered BSS/OSS at MWC Barcelona 2024

Retrieved on: 
Monday, February 5, 2024
AIM, Cerillion, Mobile World Congress, Workflow, Natural language processing, Hall, BSS, Human, Industrial design

LONDON, Feb. 5, 2024 /PRNewswire/ -- Cerillion (AIM: CER), a leading provider of BSS/OSS-as-a-Service solutions to the telecoms sector, is set to showcase its cutting-edge GenAI-powered product catalogue at MWC Barcelona 2024.

Key Points: 
  • LONDON, Feb. 5, 2024 /PRNewswire/ -- Cerillion (AIM: CER), a leading provider of BSS/OSS-as-a-Service solutions to the telecoms sector, is set to showcase its cutting-edge GenAI-powered product catalogue at MWC Barcelona 2024.
  • Cerillion invites visitors to MWC Barcelona to experience these exciting features firsthand at Hall 7, Stand 7B61.
  • "We are thrilled to showcase our latest advancements in GenAI integration at MWC Barcelona 2024," said Louis Hall, CEO, Cerillion.
  • Meet Cerillion at MWC Barcelona from 26th – 29th February where it will be showcasing its BSS/OSS product suite and GenAI integration.

PRISM MarketView Marks World Cancer Day

Retrieved on: 
Thursday, February 1, 2024
CONNECT, Melanoma, GBM, AIM, University, Breast, Prostate cancer, Acute myeloid leukemia, Renal cell carcinoma, Research, Prostate, Pancreatic cancer, Janssen Pharmaceuticals, Therapy, Patient, AML, ASCO, Temozolomide, PRISM, MD Anderson Cancer Center, FDA, Glioblastoma, Death, Rintatolimod, Glioma, Cancer, Olutasidenib, Pharmaceutical industry

NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.

Key Points: 
  • NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leading provider of unbiased market insight and company news, today recognizes the tremendous contributions of companies striving to develop treatments for cancer, a complex disease driven by numerous factors.
  • To mark World Cancer Day , which will be held on February 4, PRISM MarketView highlights emerging companies working to improve the lives of cancer patients and their families by developing and commercializing innovative new treatments for cancer.
  • The company has entered a research agreement with the Johns Hopkins University School of Medicine for the development of Ivospemin.
  • Essa Pharma, a clinical stage pharmaceutical company, is focused on the development of small molecule drugs for the treatment of prostate cancer.

Aviation Institute of Maintenance School Group Names Dr. Joel A. English as President

Retrieved on: 
Thursday, February 1, 2024
AIM, University, Old Dominion University, School, Assistant, Education, Student, Ball, Management

English has served as the institutions’ Executive Vice President since 2020, and he has functioned as Vice President of Operations, Regional Director, and Campus Executive Director since 2003.

Key Points: 
  • English has served as the institutions’ Executive Vice President since 2020, and he has functioned as Vice President of Operations, Regional Director, and Campus Executive Director since 2003.
  • Before his tenure at the institutions, Dr. English was an Assistant Professor of Professional Writing at Old Dominion University.
  • Dr. English has been a dynamic leader within the communities we serve nationwide for the past 20 years.
  • English is a champion for the communities he serves and for the students who enter the doors of our institutions.

Trial mining license at Coringa renewed for a further three years

Retrieved on: 
Wednesday, January 31, 2024
AIM, GU, ANM, FY, News, TSX, Mining, SRB, Gold, Rare-earth element

Trial mining license at Coringa renewed for a further three years.

Key Points: 
  • Trial mining license at Coringa renewed for a further three years.
  • Serabi Gold plc (“Serabi” or the “Company”) (AIM: SRB, TSX: SBI), is pleased to announce a three year renewal of the trial mining licence for its wholly owned Coringa mine (“Coringa”).
  • The National Mining Agency (ANM) has issued a renewal of the Company’s trial mining licence (“GU") for Coringa for an additional three years, demonstrating continued stakeholder support for Coringa.
  • The GU permits the transport of up to 50,000 tonnes of ore per annum from Coringa, to be processed at the Palito Complex.

Aim Security Raises $10M to Secure Generative AI Enterprise Adoption

Retrieved on: 
Wednesday, January 31, 2024
Venture Capital, Software, Internet, Data Management, Professional Services, Technology, Other Technology, Security, YL Ventures, Multimedia, Policy, Cerebral, CCL, Proofpoint, AI, Bloomberg Businessweek, Agility, Zscaler, Environment, Synthetic media, Overalls, Safety, CISO, SVP, Playboy, McKinsey & Company, Risk, AIM, Partnership, Finance, Architecture, Software as a service, WIZ, Organization, Sales

Aim Security , an Israeli cybersecurity startup offering enterprises a holistic, one-stop shop GenAI security platform, today announced $10 million in seed funding.

Key Points: 
  • Aim Security , an Israeli cybersecurity startup offering enterprises a holistic, one-stop shop GenAI security platform, today announced $10 million in seed funding.
  • Aim Security was founded by cybersecurity veterans Matan Getz, CEO and Adir Gruss, CTO who pioneered the use and adoption of AI and big data tools in the IDF’s elite intelligence Unit 8200.
  • View the full release here: https://www.businesswire.com/news/home/20240131104732/en/
    Aim Security founders (r.) Matan Getz, CEO; (l.) Adir Gruss, CTO (Photo: Business Wire)
    Generative AI isn’t the future of technology, it’s the present.
  • “This enormous risk surface is replete with unique attack vectors that existing security solutions cannot sufficiently address,” says Matan Getz, CEO and co-founder of Aim Security.

CommScope Unveils SYSTIMAX 2.0 Providing Innovative Solutions to Address Network Infrastructure Challenges

Retrieved on: 
Tuesday, January 30, 2024
Telecommunications, Construction & Property, Networks, Hardware, Building Systems, Data Management, Technology, Mobile, Wireless, Copper, Data-rate units, Intelligence, AIM, Environment, Database, Name, 2.0, COMM, CommScope, Internet service provider

For nearly 40 years, SYSTIMAX solutions have led the trajectory of tomorrow's network technologies, supporting customers’ network evolution within a fluid business environment.

Key Points: 
  • For nearly 40 years, SYSTIMAX solutions have led the trajectory of tomorrow's network technologies, supporting customers’ network evolution within a fluid business environment.
  • SYSTIMAX 2.0 enhancements carry that legacy forward, leveraging CommScope’s rich history of performance and reliability in copper, fiber and network intelligence.
  • These pillars serve as a foundation offering unparalleled solutions providing customers more options that meet their evolving network needs.
  • CommScope and the CommScope logo are registered trademarks of CommScope and/or its affiliates in the U.S. and other countries.

Falcon Oil & Gas Ltd. - Commencement of Initial Production Testing at Shenandoah South 1H

Retrieved on: 
Monday, January 29, 2024
IP30, AIM, FOG

29 January 2024 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce the commencement of the 30-day initial production (IP30) testing at the Shenandoah South 1H (“SS1H”) well in EP117, operated by Falcon Oil & Gas Australia Limited’s joint venture partner, Tamboran B2 Pty Limited.

Key Points: 
  • 29 January 2024 - Falcon Oil & Gas Ltd. (TSXV: FO, AIM: FOG) is pleased to announce the commencement of the 30-day initial production (IP30) testing at the Shenandoah South 1H (“SS1H”) well in EP117, operated by Falcon Oil & Gas Australia Limited’s joint venture partner, Tamboran B2 Pty Limited.
  • For normal operational reasons, the SS1H well was shut-in for a three week soak period and was successfully re-opened on 25 January 2024.
  • The aim of soaking was to allow for sufficient stimulation fluid to be absorbed by the shale, increasing the relative permeability to gas of the formation and enhancing future production performance.
  • The IP30 test has now commenced, and results are expected by the end of February 2024.

Q4 & Full Year 2023 Production Results and Operating Highlights

Retrieved on: 
Monday, January 29, 2024
Comex, AIM, Gold, Total, Horizontal, CapeNature, Partnership, CFA, Mining, Business development, CPA, Optimism, TSX, SRB, IPE, Probability, Workforce, News

Q4-2023 gold production of 7,891 ounces; FY2023 gold production of 33,153 ounces, a 4.2% improvement to FY2022.

Key Points: 
  • Q4-2023 gold production of 7,891 ounces; FY2023 gold production of 33,153 ounces, a 4.2% improvement to FY2022.
  • Coringa contributed 2,694 ounces of gold production in Q4 at mined grades of 6.33 g/t gold.
  • Appointed Andrew Khov, CPA, CA, CFA as its new Vice President, Investor Relations & Business Development, based in Toronto, Ontario, Canada.
  • “A satisfactory fourth quarter means gold production for the year has been 33,153 ounces which is a 4.2% improvement to 2022.

Commencement of Public Consultation in Greenland

Retrieved on: 
Friday, January 26, 2024
AIM, Environmental impact assessment, Gold, Nasdaq Iceland, Severstal, Social impact assessment

TORONTO, ONTARIO – 26 January 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to announce that the public consultation process for the draft Environmental Impact Assessment and Social Impact Assessment report on the Nalunaq Gold Mine project has commenced.

Key Points: 
  • TORONTO, ONTARIO – 26 January 2024 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ Iceland: AMRQ), an independent mine development corporation with a substantial land package of gold and strategic mineral assets across in Southern Greenland, is pleased to announce that the public consultation process for the draft Environmental Impact Assessment and Social Impact Assessment report on the Nalunaq Gold Mine project has commenced.
  • As part of the public consultation process, Amaroq management will be carrying out consultation meetings with local communities in Greenland next week.
  • The public consultation is expected to close by March 1, 2024.
  • A link to background materials regarding the public consultation is set out below: https://www.amaroqminerals.com/responsibility/#public-consultation
    A corporate video providing further background to the public consultation is available to watch at the following link: https://www.amaroqminerals.com/responsibility/#tab-publicconsultationvideo

Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

Retrieved on: 
Thursday, January 25, 2024
AIM, Patient, SOC, MDS, Decitabine, Standard of care, Survival, Faron Pharmaceuticals, PD, Quality of life, Azacitidine, Nasdaq First North, Safety, Majesty of the Seas, Myelodysplastic syndrome, Myelocyte, Pharmaceutical industry

The new analysis of data from the Phase 1 part of the trial explores the 100% overall response rate (ORR) achieved among both the higher-risk frontline and HMA-failed MDS patients treated with a bexmarilimab/azacitidine combination – 5 out of 5 patients in each population – and examines previous therapies in the patients’ treatment pathways.

Key Points: 
  • The new analysis of data from the Phase 1 part of the trial explores the 100% overall response rate (ORR) achieved among both the higher-risk frontline and HMA-failed MDS patients treated with a bexmarilimab/azacitidine combination – 5 out of 5 patients in each population – and examines previous therapies in the patients’ treatment pathways.
  • “Patients with high-risk MDS who have failed HMA therapy face a poor prognosis and median overall survival in refractory MDS is just 4-6 months with no viable treatment options.
  • Yet here we have data showing that patients are surpassing anticipated survival rates and maintaining remission.
  • It is remarkable to see patients going into remission with bexmarilimab/azacitidine after showing disease progression on all the leading azacitidine combinations such as venetoclax, sabatolimab and magrolimab.